The company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.

Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...

Investing.com -- Sarepta Therapeutics (NASDAQ: SRPT) stock soared 36% in after-hours trading Wednesday after the biotech company announced a major strategic restructuring plan designed to ensure ...

The company will pause several gene therapy development programs, for which it intends to seek partners and other strategic alternatives.

The Dow Jones Industrial Average slipped on Friday (July 18) amid reports that US President Donald Trump is pushing for ...

Stocks turned in a lackluster performance Friday as Wall Street took a breather at the end of the first week of ...

Find insight on Germany’s pharmaceutical industry, Novartis and more in the latest Market Talks covering Health Care.

Sarepta Therapeutics will cut 500 jobs and add a serious warning on the label of its muscle-disorder gene therapy Elevidys, the drugmaker said on Wednesday, following the recent deaths of two patients ...

When three patients die after taking a cutting-edge drug, most companies hit the brakes. Not Sarepta Therapeutics. The ...

Sarepta Therapeutics said on Wednesday it would lay off 36% of its workforce, or about 500 employees, after the recent deaths of two patients who had received its gene therapy Elevidys. Its shares ...

Wall Street traders have scaled back bets on interest-rate cuts after Friday’s stronger-than-expected May jobs report. Interest-rate futures ...

The Wall Street Journal conducted its quarterly survey of economists, and the outlook is cautiously optimistic for the next ...